Letters in Drug Design & Discovery publishes Original Article, Review article, Editorial, Clinical Guideline, Letters in all areas of drug design and discovery, including medicinal chemistry, in silico drug design, combinatorial chemistry, high-throughput screening, drug targets and structure-activity relationships. The emphasis is on publishing high-quality papers very quickly by making full use of the latest Internet technologies for manuscript submission and review. The journal is essential reading for all pharmaceutical scientists involved in drug design and discovery research.
Section A (Drug Design Discovery Analysis):This section focuses on all areas of drug identification, design and discovery, including medicinal chemistry, in silico drug design, combinatorial chemistry, high-throughput screening, drug targets and structure-activity relationships. It also includes neuropharmacology, ingredient activity, natural substances and biomolecules, bioimmunosuppressants and nanomaterials. In addition, this section also covers advanced technologies such as organoid chip engineering, computer-aided drug design (such as molecular modeling, structure-based drug design), and the application of multiple analytical methods such as chromatography, mass spectrometry, spectroscopy and electrochemistry.
Section B (Drug Design Biotechnology):This section focuses on the latest advances in biopharmaceutical technology, covering three major areas: organic chemistry, biology and medicine. It explores in depth various aspects of biopharmaceutical design such as antibiotics, vaccines, peptides, proteases, liposomes, polysaccharides, antibody engineering, and introduces cellular genetic engineering technologies such as high-throughput sequencing, single-cell sequencing, RNA interference, CRISPR-Cas9 gene editing, multi-omics analysis, etc. In addition, this section also focuses on the use of cellular and molecular tools (such as genes, proteins, and signaling pathways) to evaluate the effects of drugs on gene expression in cells and animal models to identify potential targets, evaluate toxicity and sensitivity, and help design, develop and discover new drugs with specific mechanisms of action. At the same time, cutting-edge technologies such as nanorobots and microbial fermentation are also the focus of this section.
Section C (Toxicology, Pharmacology, Pharmaceutics): This section focuses on the formulation, design and development of drugs, as well as the mechanism of action of drugs in organisms. It includes toxicological evaluation, pharmacodynamics, pharmacokinetics, and safety evaluation. This section involves the design and testing of drug delivery systems, including clinical trials and preclinical trials, which are essential to ensure the optimal absorption and distribution of drugs in the body. In addition, it is related to drug targets and disease treatment in various departments, aiming to discover and optimize drug design and development.
Part D (Pharmaceutical Sciences): This part focuses on the discovery, development, evaluation, and regulation of drugs and therapies. The primary goal is to enhance human health by developing new pharmaceutical products, improving drug delivery methods, and ensuring the safety and effectiveness of therapeutics.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International License.
Member of
